Search Weight Loss Topics:

Page 3«..2345..1020..»

Home » Hgh » Page 3

Robina Weermeijer

By Isobel Williams via SWNS

A growth hormone given to children that was banned in 1985 has been shown to have caused Alzheimer's disease, a new study has revealed.

The hormone, derived from the pituitary gland of human corpses, was known as c-hGH or cadaver-derived human growth hormone.

It was used to treat at least 1,848 people of short stature in the UK between 1959 and 1985.

It was banned after some batches were contaminated with infectious proteins, or prions, which had caused Creutzfeldt-Jakob disease (CJD) a brain disease, in some people.

CJD normally proves fatal within eight months. A variant of CJD was known as mad cow disease

It has now been discovered that this treatment also left prematurely developed deposits of the amyloid-beta protein in participants brains, which is the cause of Alzheimers.

A team from University College London Hospital have now shown that at least five recipients of c-hGH developed Alzheimer's as a result.

Professor John Collinge from UCLH said: There is no suggestion whatsoever that Alzheimers disease can be transmitted between individuals during activities of daily life or routine medical care.

The patients we have described were given a specific and long-discontinued medical treatment which involved injecting patients with material now known to have been contaminated with disease-related proteins.

However, the recognition of transmission of amyloid-beta pathology in these rare situations should lead us to review measures to prevent accidental transmission via other medical or surgical procedures, in order to prevent such cases occurring in future.

Importantly, our findings also suggest that Alzheimer's and some other neurological conditions share similar disease processes to CJD, and this may have important implications for understanding and treating Alzheimers disease in the future.

Photo by cottonbro studio via Pexels

To get their results, published in the journal Nature Medicine, the team studied eight people referred to UCLHs National Prion Clinic at the National Hospital for Neurology and Neurosurgery in London, who had all been given this treatment in childhood.

They found that five of these people had symptoms of dementia, and either had already been diagnosed with Alzheimers disease or would meet the diagnostic criteria for this condition.

Another person was found to have met the criteria for mild cognitive impairment, and all these people were between 38 and 55 years old when they started having neurological symptoms.

The unusually young age at which these patients developed symptoms suggests they did not have the usual sporadic Alzheimers which is associated with old age.

In the five patients in whom samples were available for genetic testing, the team also ruled out inherited Alzheimers disease.

The researchers stress that this is extremely rare, and now that the treatment is no longer in use there is no risk of any new transmission.

Professor Jonathan Schott said: It is important to stress that the circumstances through which we believe these individuals tragically developed Alzheimers are highly unusual, and to reinforce that there is no risk that the disease can be spread between individuals or in routine medical care.

These findings do, however, provide potentially valuable insights into disease mechanisms, and pave the way for further research which we hope will further our understanding of the causes of more typical, late onset Alzheimers disease.

See original here:
Researchers find tie between banned growth hormone and Alzheimer's - NBC Right Now

Credit: Pixabay.

Alzheimers disease, a devastating neurological condition affecting people in late adulthood, may have been acquired by five individuals through medical treatments received decades ago. This marks the first instance of Alzheimers in living patients potentially linked to medical procedures.

The individuals in question were treated as children with cadaver-derived human growth hormone (c-hGH), extracted from the pituitary glands of deceased donors. This treatment was administered to at least 1,848 people in the UK between 1959 and 1985 for various forms of short stature. The practice was discontinued in 1985 after it was discovered that some batches of c-hGH were contaminated with infectious proteins called prions, responsible for Creutzfeldt-Jakob disease (CJD) in some patients. Fortunately, this medication was replaced a long time ago by synthetic growth hormone, which is free from the risk of transmitting CJD.

The same researchers previously found that some patients with CJD due to c-hGH treatment had also developed deposits of amyloid-beta protein in their brains prematurely. Further research in 2018 revealed that archived samples of c-hGH were contaminated with amyloid-beta protein. When injected into laboratory mice, these samples transmitted amyloid-beta pathology, suggesting that long-term survivors of c-hGH treatment might develop Alzheimers disease.

Amyloid-beta, a fragment produced from a larger precursor protein, is now considered a hallmark of Alzheimers. Patients with this condition have unusually high quantities of amyloid-beta in their brains.

In a healthy brain, amyloid-beta plays various roles, including regulating neural activity and supporting brain health. However, in Alzheimers disease, something goes awry. The protein begins to accumulate, forming clumps and eventually dense, insoluble plaques that disrupt brain function. This process is believed to be a critical factor in the onset and progression of Alzheimers, but the exact reasons why and how this accumulation occurs remain one of the great mysteries of modern neuroscience.

The new study focuses on eight individuals who received c-hGH treatment in childhood. The patients were admitted to the University College Londons National Prion Clinic at the National Hospital for Neurology and Neurosurgery. Among them, five displayed dementia symptoms consistent with Alzheimers disease or met the diagnostic criteria for it.

What is striking is their age range: 38 to 55 years when symptoms appeared, far younger than the typical onset age for sporadic Alzheimers in the mid-60s or later. Genetic testing ruled out inherited Alzheimers in these patients.

The c-hGH treatment is now obsolete, so there is no risk of new transmissions via this route. The authors of the study emphasize that the circumstances of these Alzheimers cases are highly unusual and that the disease cannot be spread through daily contact. There is no way you can get Alzheimers through close contact or routine care of a patient that was never a remote possibility.

However, now that this old treatment has been strongly linked to acquired Alzheimers, one can only wonder if other treatments, discontinued or otherwise, may also be responsible for Alzheimers.

The recognition of transmission of amyloid-beta pathology in these rare situations should lead us to review measures to prevent accidental transmission via other medical or surgical procedures, to prevent such cases from occurring in the future, said lead author Professor John Collinge, Director of the UCL Institute of Prion Diseases.

Importantly, our findings also suggest that Alzheimers and some other neurological conditions share similar disease processes to CJD, and this may have important implications for understanding and treating Alzheimers disease in the future.

The findings appeared in the journal Nature Medicine.

Go here to read the rest:
Scientists document first cases of acquired Alzheimer's due to decades-old childhood treatment - ZME Science

LONDON A growth hormone administered to children, banned since 1985, is now displaying a link to Alzheimers disease. This hormone, extracted from the pituitary glands of human corpses, is called cadaver-derived human growth hormone (c-hGH). From 1959 to 1985, researchers in the United Kingdom say doctors administered it to at least 1,848 individuals dealing with growth deficiencies.

The use of c-hGH stopped after scientists discovered that some batches were contaminated with infectious proteins called prions. These contaminants were responsible for causing Creutzfeldt-Jakob disease (CJD), a fatal brain condition, among some recipients. CJD typically leads to death within eight months. A variant of CJD commonly goes by the name mad cow disease.

Recent findings indicate that this treatment also resulted in premature development of amyloid-beta protein deposits in the brains of participants, a known cause of Alzheimers disease. Researchers from University College London Hospital have now demonstrated that at least five individuals who received c-hGH subsequently developed Alzheimers as a consequence.

There is no suggestion whatsoever that Alzheimers disease can be transmitted between individuals during activities of daily life or routine medical care. The patients we have described were given a specific and long-discontinued medical treatment which involved injecting patients with material now known to have been contaminated with disease-related proteins, says study lead author Professor John Collinge, Director of the UCL Institute of Prion Diseases and a consultant neurologist at UCLH, in a media release.

However, the recognition of transmission of amyloid-beta pathology in these rare situations should lead us to review measures to prevent accidental transmission via other medical or surgical procedures, in order to prevent such cases occurring in future, Prof. Collinge continues.

Importantly, our findings also suggest that Alzheimers and some other neurological conditions share similar disease processes to CJD, and this may have important implications for understanding and treating Alzheimers disease in the future.

In their study, published in Nature Medicine, the researchers at University College London Hospitals National Prion Clinic, based at the National Hospital for Neurology and Neurosurgery in London, examined eight individuals. These individuals, who all received the controversial treatment during childhood, were referred to the clinic.

The team discovered that five of these individuals exhibited symptoms of dementia. They had either already been diagnosed with Alzheimers disease or met the diagnostic criteria for the condition. Additionally, another individual was identified as meeting the criteria for mild cognitive impairment. Notably, these patients were between 38 and 55 years-old when they first exhibited neurological symptoms, which is unusually young. This early onset of symptoms indicates that their condition differed from the typical sporadic Alzheimers disease, which is commonly associated with older age.

Furthermore, in the five patients for whom genetic testing samples were available, the researchers ruled out the possibility of inherited Alzheimers disease. The researchers emphasized that this situation is extremely rare. Additionally, they reassured us that since the implicated treatment is no longer in use, there is no risk of new cases arising from this cause.

It is important to stress that the circumstances through which we believe these individuals tragically developed Alzheimers are highly unusual, and to reinforce that there is no risk that the disease can be spread between individuals or in routine medical care, concludes study co-author Professor Jonathan Schott from the UCL Queen Square Institute of Neurology.

These findings do, however, provide potentially valuable insights into disease mechanisms, and pave the way for further research which we hope will further our understanding of the causes of more typical, late onset Alzheimers disease. South West News Service writer Isobel Williams contributed to this report.

Read more:
Banned growth hormone linked to Alzheimer's disease -- Former child patients at risk - Study Finds

A medical treatment given to children in the UK may have led to some developing Alzheimers disease decades later, new research out Monday suggests. The study presents evidence that at least five people contracted the neurodegenerative disorder from having received human growth hormones contaminated with rogue amyloid beta protein. The authors point out that Alzheimers cannot be caught person-to-person through conventional means, however, and this specific infection risk no longer exists today.

Alex Winter on Innovative Horror Movies

Starting in the 1950s, scientists learned how to extract human growth hormone (HGH) from the pituitary glands of cadavers. Unfortunately, the method only provided minute amounts of hormone at a time, which limited the supply of HGH available for medical and research purposes. As a result, its distribution was meticulously handled, and it was typically only given to treat the most severe growth-related conditions in children.

This remained the status quo for the next 30 years, with more than 20,000 children worldwide having received this form of cadaver-derived HGH. But in the mid-1980s, health officials in the U.S. and elsewhere began to get unusual reports of people coming down with Creutzfeldt-Jakob disease (CJD), a rare but universally fatal neurodegenerative disease. These cases were happening in much younger people than typically seen with CJD, and it was soon discovered those affected shared a history of past HGH treatment. Within months of this discovery, the U.S. and other countries shut down their cadaver HGH programs.

These cases, as it turned out, were caused by HGH seeded with a persons misfolded prionsmutinous proteins that eat away at the brain by gradually transforming normal prions into their misfolded form. It can take years to decades before the symptoms of a prion disease appear, explaining why it took so long for the connection to be discovered. As of today, there have been around 220 cases of Creutzfeldt-Jakob disease linked to cadaver-derived HGH, with some showing up to 40 years later.

Researchers at the University of College London have continued to keep track of potential cases of illness tied to HGH. And over time, theyve come across patients who seem to have avoided CJD but have developed other neurological conditions, including Alzheimers disease. In a paper published in Nature Medicine Monday, they argue that these cases represent a rare but real form of transmissible Alzheimers.

The paper details eight patients who visited the UCLs National Prion Clinic. Five of them appear to have developed early onset Alzheimers, with a sixth having mild cognitive impairment. But none of the patients seemed to have known genetic mutations that cause Alzheimers to happen at a younger age or other shared factors besides a past history of HGH treatment.

Alzheimers is caused by the build-up of two misfolded proteins in the brain, amyloid beta and tau, with amyloid beta seen as the driving force of the two. The teams past research has found amyloid beta inside the brains of people who died from HGH-caused Creutzfeldt-Jakob disease, as well as inside samples of preserved HGH. And in the lab, theyve been able to successfully cause mice to develop Alzheimers-like illness after exposing them to these contaminated samples.

Put all the pieces together, the study authors say, and its enough to show that Alzheimers disease should now be recognized as a potentially transmissible disorder.

The teams work is the latest to suggest that Alzheimers and other neurodegenerative conditions have a lot in common with prion diseases like CJD (some scientists have even argued that they effectively are prion diseases). Prion diseases are usually inherited or occur spontaneously, for instance, but have rarely been transmitted through contaminated beef or the ritualistic cannibalism of human brains, in addition to HGH treatments. At the same time, people shouldnt be worried about catching Alzheimers or prion diseases like they would a typical infectious germ, like a virus. And scientists eventually learned how to synthesize HGH in the lab that carries no risk of prion or amyloid contamination. This version was given regulatory approval soon after the cadaver programs were shut down.

It is important to stress that the circumstances through which we believe these individuals tragically developed Alzheimers are highly unusual, and to reinforce that there is no risk that the disease can be spread between individuals or in routine medical care, said study author Jonathan Schott, a UCL neurologist and chief medical officer at Alzheimers Research UK, in a statement from the university. These findings do, however, provide potentially valuable insights into disease mechanisms, and pave the way for further research which we hope will further our understanding of the causes of more typical, late onset Alzheimers disease.

Here is the original post:
Scientists Find Evidence Alzheimer's Can Be Transmissible - Gizmodo

Florida, a state blessed with incredibly beautiful beaches and inviting weather, is not just a popular tourist destination. It's also home to a growing trend in the field of healthcareHuman Growth Hormone (HGH) therapy. In the Sunshine State, many individuals are turning to HGH therapy not only for its well-known anti-aging benefits but also for its remarkable ability to strengthen bones and joints. This article explores the role of human growth hormone therapy Florida in improving bone and joint health and how it's making a difference in the lives of many Floridians.

Understanding HGH Therapy

Human Growth Hormone (HGH) is a hormone that your body makes on its own, thanks to a special gland in the brain called the pituitary gland. This hormone is really important because it helps the body grow, repair itself, and stay healthy. But as you get older, the body makes less of this hormone. That can cause problems like weaker bones and joints.

The Impact of Aging on Bone and Joint Health

Florida, with its sizable senior population, faces significant challenges related to bone and joint health. Aging is often accompanied by conditions like osteoporosis and osteoarthritis, resulting in fragile bones and painful joints. These issues can affect mobility, independence, and overall quality of life.

HGH Therapy's Role in Strengthening Bones

One of the most promising aspects of HGH therapy is its ability to increase bone density. This benefits older individuals in Florida, where osteoporosis is a prevalent concern. HGH therapy stimulates bone growth and mineralization, making bones stronger and less susceptible to fractures.

HGH therapy can help in the healing of bone injuries and fractures. In Florida's active lifestyle, where accidents can happen, the ability to recover from bone injuries more rapidly is a significant advantage.

Enhancing Joint Health with HGH Therapy

Florida's warm climate encourages an active lifestyle, but joint problems can hinder this enjoyment. HGH therapy can also play a pivotal role in improving joint health. It stimulates collagen production, a vital component of cartilage that cushions and protects joints.

As collagen levels increase, joints become more resilient, reducing the risk of conditions like osteoarthritis. Many Floridians have found that HGH therapy allows them to continue enjoying outdoor activities like golf, tennis, and swimming well into their golden years.

Individualized Treatment Plans in Florida

One of the advantages of pursuing HGH therapy in Florida is the availability of specialized clinics that offer individualized treatment plans. These plans meet each patient's unique needs, taking into account their age, health status, and lifestyle.

Before beginning HGH therapy, patients typically undergo a comprehensive evaluation, including blood tests and a medical history review. This helps healthcare providers in Florida determine the appropriate dosage and treatment duration, ensuring optimal results while minimizing potential risks.

Safety and Monitoring

Patient safety is a top priority in Florida's HGH therapy clinics. Regular monitoring ensures the therapy is effective and safe. During the course of treatment, patients undergo periodic check-ups, including blood tests, to assess hormone levels and overall health.

Clinicians in Florida work closely with patients to monitor their progress and make necessary adjustments to their treatment plans. This personalized approach helps patients receive the maximum benefits of HGH therapy while minimizing any potential side effects.

Human growth hormone therapy in Florida is making a significant difference in the lives of those seeking to strengthen their bones and joints. With its ability to increase bone density, promote collagen production, and enhance joint health, this therapy is helping individuals maintain their mobility and independence well into their later years.

Continued here:
HGH Therapy in Florida: Strengthening Bones and Joints - Yes! Weekly

The worldwide human growth hormone treatment and drugs market including human growth hormone is anticipated to reach a value of US$ 3.55 billion by the end of 2022. The market is anticipated to expand at a compound annual growth rate (CAGR) of 3.7% from 2023 to 2033, reaching a market value of around US$ 5.26 billion by that time.

Industry participants investments, the presence of a solid pipeline, extensive R&D efforts, a comprehensive product portfolio, and expanding government initiatives are all projected to drive the demand for human growth hormone treatment & drugs.

Human growth hormone manufacturers are investing in research and development to create a growth hormone with fewer side effects and the potential to be a long-term treatment.

The human growth hormone supplements market is growing due to an increase in disorders connected to growth hormone insufficiency, an increase in the use of ageing hormones, government and private sector efforts to raise awareness of growth hormone deficit, and high productivity. Other reasons such as greater understanding of the treatment process, an increase in the number of health conditions, and an increase in the number of neuropsychiatric cases are expected to boost the human growth hormone treatment & drugs market sizes growth. Human growth hormone supplements market expansion is projected to be driven by the quick growth of new human growth hormone novels.

Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14401

As per the global human growth hormone treatment & drugs market study, the industry is likely to be driven by initiatives taken by various government and private organizations to raise awareness about GH deficiency and human growth hormone treatment.

International Childrens Growth Awareness Day is observed every year by the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a nonprofit charitable organization based in the United States, to increase public knowledge regarding the early detection and intervention of human growth hormone problems, particularly in children.

However, the high price of hGH therapies, as well as severe hGH-related side effects, may negatively impact the human growth hormone for sale over the projection period.

Knee, hip, or other joint discomforts; allergic reactions, such as redness, swelling, or hives; and an increase in blood sugar levels are all possible adverse effects of GH hormone therapy, according to UPMC Childrens Hospital of Pittsburgh.

Key Takeaways:

Unlock exclusive insights with our expert analysts: https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-14401

A healthy product portfolio and extensive Market research investments for the emergence of future growth hormone treatments are projected to propel the sales of human growth hormone treatment & drugs.

Competitive Landscape :

The demand for human growth hormone treatment & drugs is moderately concentrated, with a few key manufacturers owning a large portion of the industry. Furthermore, several active collaborations are underway to generate more effective and long-acting subtypes of human growth hormones.

Key human growth hormone manufacturers include:

Pfizer Inc. began a Phase III research trial in February 2021 to assess the efficacy and security of somatropin in a group of Japanese patients with Prader-Willi Syndrome (PWS).

In October 2020, Erasmus Medical Center, in collaboration with Pfizer, the Foundation for Prader-Willi Research, and the Prader-Willi Fonds, launched a Phase III clinical trial to evaluate the impact of growth hormone treatment (Genotropin) on physical and psychosocial wellbeing in adults with Prader-Willi syndrome who are 30 years or older.

Unlock Tailored Insights: Customize Your Report for Maximum Impact: https://www.futuremarketinsights.com/customization-available/rep-gb-14401

Key Market Segments Covered in Human Growth Hormone Treatment and Drugs Market Industry :

By Route of Administration:

By Application:

By Distribution Channel:

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware 19713, USA T: +1-845-579-5705

For Sales Enquiries:sales@futuremarketinsights.com Website:https://www.futuremarketinsights.com LinkedIn|Twitter|Blogs | YouTube

Read more:
Human Growth Hormone Treatment and Drugs Market Foresees a ... - PharmiWeb.com

A SUM of RM3,911,853 was raised at a charity dinner and concert to benefit UTAR Hospital in Kampar, Perak.

The fundraising, part of UTAR Hospitals final push to garner donations for its development fund, was in part made possible by the Tiger Sin Chew Chinese Education Charity Concert (TSCCECC) programme.

Over 64 tables were sold and more than 1,000 guests attended the event, which took place at HGH Convention Centre in Sentul, Kuala Lumpur.

(From left) Wu, Yee Yee, Lee, Z Yan, Chiang and Jyin performing on stage.

Universiti Tunku Abdul Rahman (UTAR) president and chief executive officer Prof Datuk Dr Ewe Hong Tat said the money collected from the fundraiser would go towards the hospitals development.

Since construction work began in 2018, we had set a target of collecting RM330mil.

To date, we have reached the RM300mil mark.

Special welcome - Guests greeting the arrival of Dr. Ling (seated in wheelchair) and flanked by Heng at the concert. - Photos: CHAN TAK KONG/The Star

The funds will allow us to provide additional services such as establishing the specialist centre for orthopaedics, internal medicine, paediatrics, obstetrics and gynaecology.

The help of philanthropists, charitable societies and generous donors from the community over the years has allowed the hospital to begin operations, said Prof Ewe.

Freddie and the Catz performing during charity dinner show in benefit of UTAR Hospital at the HGH Convention Centre. - Photos: CHAN TAK KONG/The Star

A non-profit entity, UTAR Hospital offers western as well as traditional and complementary medicine.

Among those who had contributed was the event venue, HGH Convention Centre.

The centres management committee chairman Datuk Eddie Heng said that they had agreed to provide the venue, food and special effects such as stage lighting.

At the fundraiser were (from left) UTAR council members Datuk Lim Si Cheng and Hew Fen Yee, Prof Ewe, Prof Chuah, UTAR Institute of Chinese Studies dean Assoc Prof Dr Chong Siou Wei, Dr Ling, Roland, Koo Cheng and Heng. Photos: CHAN TAK KONG/The Star

He estimated that the package was worth over RM120,000.

We agreed to this because we saw it as a worthy cause.

It is a non-profit hospital which charges nominal fees but offers quality care.

When one is sick, every minute is torture and every second feels like a struggle for survival.

If we can play a part to provide relief to the sick, then why not? said Heng.

The TSCCECC is part of Heineken Malaysia Bhds social impact programme.

Yee Yee captivating her audience.

Since its inception in 1994, it has raised more than RM390mil for 538 schools.

This is the first year the social impact programme has extended its support to a hospital.

Heineken Malaysia managing director Roland Bala said the programmes sustainability was fuelled by the Chinese communitys commitment to education.

In life, there are two things that can make a difference.

One is a deep sense of values. Another is good education.

This is why the Chinese community has achieved so much progress.

No matter their financial background they will never stinge on, much less forgo education for their children, said Roland.

Expressing her delight at the donors generous contributions was the brewers marketing director Willemijn Sneep.

Our initial target was RM3mil but the total collected exceeds our expectations, she said.

For the opening act, dancers, clad in silver sequined bodysuits took to the stage.

This was followed by artists Wu Jia Hui, Yee Yee, Victor Lee, Z Yan, Zac Chi Chiang and Jyin.

Making special appearances were guest singer Chris Cheong, who won the Astro 2020 Classic Golden Melody Singing Competition, and Malaysian Chinese music group Freddie and The Catz.

Attending the event as guests of honour were UTAR chancellor Tun Dr Ling Liong Sik and wife Toh Puan Ena Ling.

Also present were UTAR Hospital board chairman Emeritus Prof Tan Sri Dr Chuah Hean Teik and Sin Chew Media Corporation Bhd executive director Koo Cheng.

Read more here:
RM3.9mil raised in aid of UTAR Hospital - The Star Online

Modified Apr 20, 2023 15:32 GMT

Roger Clemens was a star MLB player and one of the best hitters of all time.

Debbie Clemens, his wife, allegedly received HGH shots in secret without telling him in 2012. Clemens' trainer injected the star's wife with HGH.

The night after getting the shot, Debbie Clemens claimed that she struggled to fall asleep due to circulation issues. She described calling her husband and telling him about the injection. She said that Roger Clemens "wasn't happy with Brian" about it and that she wasn't "old enough yet" in her husband's eyes.

The former pitching ace admitted during his 2012 perjury trial that her husband's former trainer had given her a dose of the human growth hormone.

Roger Clemens was allegedly one of many players who used PEDs in 2006, according to former pitcher Jason Grimsley's federal complaint.

Andy Pettitte, a former New York Yankees pitcher and Clemens' teammate, testified that Clemens acknowledged using the human growth hormone between 1999 and 2000. He later explained that he was referring to his wife's drug use.

The Chicago Tribune reports that Clemens' agent, Randy Hendricks, angrily refuted the allegations and Clemens' use of performance-enhancing drugs in 2006.

Roger Clemens was facing a second trial on federal charges of lying to a U.S. congressional committee following his denial of using PEDs.

The House of Representatives Oversight and Government Reform Committee was investigating drug use in Major League Baseball at the time.

See the rest here:
"I'm not ashamed of taking that shot...I'm embarrassed that it went across the world" - When Roger Clemens' trainer injected star's wife -...

A workout that works twice as hard, so we dont have to? Sign. Us. Up.

We are major fans of efficiency when it comes to fitness, which is why we are totally into Rachael Blumbergs fitness creation, PlateFita fitness class that uses a vibrating plate to burn twice the cals in half the time.

In fact, we love it so much, we hosted a PlateFit workout at Camp Poosh this year.

There is something magical, and yet very scientific, about spending time on vibration. This metaphysical experience and its visceral results are so powerful. It changed the trajectory of my life after just 30 seconds on the plate, and its why I continue sharing vibration with others, Rachael says.

Below, we catch up with her to learn more about the mind, body, and beauty benefits of this high-vibe workout.

What is PlateFit?

We cultivate transformation and whole body wellness through the science of vibration, Rachael tells us. Our signature, 27-minute PlateFit classes support muscle recovery, strengthen and elongate the body, detoxify the system, and help you vibrate higher.

How does it work?

PlateFit classes use medical-grade devices that emit rapid harmonic vibrations to destabilize the body, Rachael says. Your muscles reflexively work harder to keep you stabilized.

The plates move in three directions at once: left to right, front to back, up and down, she says. During our workout classes, muscles contract 30 to 50 times per second! Thats roughly 900 to 1,500 contractions every 30 seconds.

What are the benefits?

BodyToned musclesIncreased strengthImproved enduranceImproved flexibilityBetter balance and coordinationFaster metabolismImproved circulationFat loss

MindDecreased cortisol levelsIncreased serotoninImproved sleep

BeautyIncreased HGH (a hormone that stimulates cell growth and regeneration)Brighter, glowing skinFlushed lymphatic system

Will any vibrating plate work?

In short: no.

There are several vibrating plate machines on the market. but the technology and the way in which the vibration is created is not the same, Rachael says. I choose to work exclusively with PowerPlate machines as they are certified medical devices, backed by years of research and development. PowerPlate also continues to study vibration, which holds so much value as were endlessly learning about the human body.

How long do you need to work out on the plate?

Twenty-seven minutes is all you need, according to Rachael. She recommends four classes a week, plus two of their deep recovery classes.

The content provided in this article is provided for information purposes only and is not a substitute for professional advice and consultation, including professional medical advice and consultation; it is provided with the understanding that Poosh, LLC (Poosh) is not engaged in the provision or rendering of medical advice or services. The opinions and content included in the article are the views of the interviewee only, and Poosh does not endorse or recommend any such content or information, or any product or service mentioned in the article. You understand and agree that Poosh shall not be liable for any claim, loss, or damage arising out of the use of, or reliance upon any content or information in the article.

Up next, be the first to know our weekly content and sign up for our Poosh newsletter.

See the original post:
This Vibrating Fitness Plate Cuts Your Workout in Half - Poosh

PRESS RELEASE

Published April 19, 2023

An international Achondroplasia business research document studies the key factors affecting the market and various opportunities in the market. Moreover, the report aims to examine the overall size of the market and infer the key trends from it. To inspect the market based on market share, product, and product share. Market instructions provided in this market analysis report are very specific and research-backed. They have been created to help players move in the right direction during their journey to achieve success in the market. Achondroplasia report also evaluates the market on the basis of end-users and applications and focus on the growth rate of each application.

The persuasive Achondroplasia Market research reports will be favorable for new comers/new investors, propose investors and private equity enterprises, analysts and prudent business organizers, suppliers, manufacturers, and distributors, and end-use industries. For getting customization of the report, reach DBMR team via email or phone. If there is any special business requirement or necessity of a point by point of the whole research, dont mind, let us know and get the report as needed. Achondroplasia market report enables clients to enhance business efficiency and focus on other core aspects of operations rather than wasting time in market research and reporting needs.

Data Bridge Market Research analyses a growth rate in the global achondroplasia market in the forecast period 2022-2029. The expected CAGR of global achondroplasia market is tend to be around 36.5% in the mentioned forecast period. The market was valued at USD 68.73 million in 2021, and it would grow upto USD 828.34 million by 2029.

Arachnoiditis is also known as achondroplasia dwarfism, which is the bone growth disorder and the most common form of short-limbed dwarfism. It is largely characterized by short stature and short limbs. The genetic defect can be passed from parent to child. Although, in around 80% of instances, achondroplasia is caused by a spontaneous mutation that originates in the developing embryo. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Download Sample PDF Copy Of This Report To Understand Structure Of The Complete Report (Including Full TOC, Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-achondroplasia-market

Market Overview

Drivers

The growing prevalence of achondroplasia is projected to drive the market growth during the forecast period. For instance, as per the data published by the European Medicines Agency in June 2021, it is projected that 350 children are born with achondroplasia each year in Europe. This boosts the market growth.

The increasing number of drug approvals and launches by major market players is expected to drive market growth. For example, Ascendis Pharma A/S announced on January 13, 2022, that the European Commission (EC) approved TransCon hGH as a once-weekly subcutaneous injection to treat paediatric patients experiencing growth failure due to insufficient endogenous growth hormone secretion or growth hormone deficiency. TransCon hGH contains Somatropin, which delivers unmodified Somatropin (hGH) to the body in therapeutic quantities.

Global Achondroplasia Market Scope And Market Size

The global achondroplasia market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

Route of Administration

Hospitals

Distribution Channel

Browse More About This Research Report @

https://www.databridgemarketresearch.com/reports/global-achondroplasia-market

Key players operating in the global achondroplasia market include:

Get The Full Table Of Contents @

https://www.databridgemarketresearch.com/toc/?dbmr=global-achondroplasia-market

About Data Bridge Market Research:

An Absolute Way To Predict What The Future Holds Is To Understand The Current Trend! Data Bridge Market Research Presented Itself As An Unconventional And Neoteric Market Research And Consulting Firm With An Unparalleled Level Of Resilience And Integrated Approaches. We Are Committed To Uncovering The Best Market Opportunities And Nurturing Effective Information For Your Business To Thrive In The Marketplace. Data Bridge Strives To Provide Appropriate Solutions To Complex Business Challenges And Initiates An Effortless Decision-Making Process. Data Bridge Is A Set Of Pure Wisdom And Experience That Was Formulated And Framed In 2015 In Pune.

Data Bridge Market Research Has More Than 500 Analysts Working In Different Industries. We Have Served More Than 40% Of The Fortune 500 Companies Globally And Have A Network Of More Than 5,000 Clients Worldwide. Data Bridge Is An Expert In Creating Satisfied Customers Who Trust Our Services And Trust Our Hard Work With Certainty. We Are Pleased With Our Glorious 99.9% Customer Satisfaction Rating.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

United Kingdom: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [emailprotected]

See the original post here:
Emerging Trends and Opportunities in the Achondroplasia Market ... - Digital Journal

Page 3«..2345..1020..»

Home » Hgh » Page 3